SEC Form 4 · accession 0001325812-15-000052
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Akshay Vaishnaw
Officer — EVP, R&D, CMO
Period of report
Jun 16, 2015
Accepted (ET)
Jun 18, 2015 · 4:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 16, 2015 | M | 6,250 | $9.30 | A | 6,250 | D | |
| Common Stock | Jun 16, 2015 | M | 2,500 | $7.10 | A | 8,750 | D | |
| Common StockF2 | Jun 16, 2015 | S | 3,933 | $128.0983 | D | 4,817 | D | |
| Common StockF3 | Jun 16, 2015 | S | 2,667 | $128.7885 | D | 2,150 | D | |
| Common StockF4 | Jun 16, 2015 | S | 1,800 | $130.0554 | D | 350 | D | |
| Common StockF5 | Jun 16, 2015 | S | 350 | $130.9986 | D | 0 | D | |
| Common StockF6 | holding | — | — | — | 103 | I | by Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F7 | $7.10 | Jun 16, 2015 | M | 2,500 | D | — | Nov 30, 2021 | Common Stock | 2,500 | 5,000 | D |
| Stock Option (right to buy)F7 | $9.30 | Jun 16, 2015 | M | 6,250 | D | — | Jun 9, 2021 | Common Stock | 6,250 | 0 | D |
Explanation of responses
- F1The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2013
- F2Sale prices ranged from $127.49 to $128.46.
- F3Sale prices ranged from $128.49 to $129.38.
- F4Sale prices ranged from $129.55 to $130.50.
- F5Sale prices ranged from $130.57 to $131.22.
- F6The reporting person owns 103 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F7The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.